SQZ play: Roche doubles down on a $1.37B-plus deal for a new approach to immuno-oncology out of Bob Langer's lab
Whatever Roche $ROG learned about SQZ over the last 33 months clearly only whetted their appetite for much, much more.
This morning SQZ is unveiling a revise-replace-and-expand development pact with the Watertown, MA-based biotech, one of many to emerge from the lab of MIT’s Bob Langer.
In this new deal Roche is putting up $125 million for an upfront and near-term milestones in a collaboration deal embedded with $1 billion in development goal money. Another $250 million is on the line for each new therapy that manages to make it all the way to an approval.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters